Cargando…

Serum IgG as a Marker for Opisthorchis viverrini-Associated Cholangiocarcinoma Correlated with HER2 Overexpression

BACKGROUND: Serum antibody for Opisthorchis viverrini (OV) is strong evidence for a history of OV infection in people. Currently, no studies have examined whether varying cholangiocarcinoma (CCA) prevalence levels are linked to previous OV infection nor have they provided comprehensive assessment an...

Descripción completa

Detalles Bibliográficos
Autores principales: Titapun, Attapol, Techasen, Anchalee, Sa-Ngiamwibool, Prakasit, Sithithaworn, Paiboon, Luvira, Vor, Srisuk, Tharatip, Jareanrat, Apiwat, Dokduang, Hasaya, Loilome, Watcharin, Thinkhamrop, Bandit, Khuntikeo, Narong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708780/
https://www.ncbi.nlm.nih.gov/pubmed/33273846
http://dx.doi.org/10.2147/IJGM.S282519
_version_ 1783617610788634624
author Titapun, Attapol
Techasen, Anchalee
Sa-Ngiamwibool, Prakasit
Sithithaworn, Paiboon
Luvira, Vor
Srisuk, Tharatip
Jareanrat, Apiwat
Dokduang, Hasaya
Loilome, Watcharin
Thinkhamrop, Bandit
Khuntikeo, Narong
author_facet Titapun, Attapol
Techasen, Anchalee
Sa-Ngiamwibool, Prakasit
Sithithaworn, Paiboon
Luvira, Vor
Srisuk, Tharatip
Jareanrat, Apiwat
Dokduang, Hasaya
Loilome, Watcharin
Thinkhamrop, Bandit
Khuntikeo, Narong
author_sort Titapun, Attapol
collection PubMed
description BACKGROUND: Serum antibody for Opisthorchis viverrini (OV) is strong evidence for a history of OV infection in people. Currently, no studies have examined whether varying cholangiocarcinoma (CCA) prevalence levels are linked to previous OV infection nor have they provided comprehensive assessment and characterization of OV-associated CCA. OBJECTIVE: Our study examined the prevalence of serum IgG antibodies for OV-positive CCA cases and determined whether there were correlations of IgG antibodies with histopathologic features, HER2, PD-L1, and FGFR2 expression, as well as their roles on the patients’ survival. METHODS: The study involved 221 CCA surgical patients at Khon Kaen University Hospital, Thailand, from 2005 to 2017. Serum specimens were tested for OV IgG by ELISA. CCA tissue microarrays were used to examined for HER2, PD-L1, and FGFR2 expression. Logistic regression was used to investigate an association between factors and IgG. Cox regression was used to determine factors that affected CCA patient survival. RESULTS: IgG for OV were positive in 162 cases, and the prevalence was 73.3% (95% CI=68.0–78.7). About three quarters (78.3%) had large duct type tumors and concomitant intraductal papillary neoplasm of bile ducts (IPNB) occurred in 92 (50%) cases. HER2 expression was positive in 94 (61.4%) cases. Positive PD-L1 and FGFR2 expression occurred in 125 (83.9%) and 100 (67.1%) cases. IgG for OV had no significant correlation to any histological feature but had significant correlation with HER2 overexpression with adjusted OR=2.32 (95% CI=1.09–4.96, P=0.03). Cases of CCA with OV IgG positive had a significantly poor prognosis with adjusted HR=1.66 (95% CI=1.13–2.43, P=0.01). CONCLUSION: We found a high prevalence of serum IgG for OV-positive CCA patients and a correlation with overexpression of HER2. Moreover, IgG for OV and HER2 expression indicated poor survival of CCA. Therefore, future clinical studies for anti-HER2 treatments should focus on OV-associated CCA.
format Online
Article
Text
id pubmed-7708780
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77087802020-12-02 Serum IgG as a Marker for Opisthorchis viverrini-Associated Cholangiocarcinoma Correlated with HER2 Overexpression Titapun, Attapol Techasen, Anchalee Sa-Ngiamwibool, Prakasit Sithithaworn, Paiboon Luvira, Vor Srisuk, Tharatip Jareanrat, Apiwat Dokduang, Hasaya Loilome, Watcharin Thinkhamrop, Bandit Khuntikeo, Narong Int J Gen Med Original Research BACKGROUND: Serum antibody for Opisthorchis viverrini (OV) is strong evidence for a history of OV infection in people. Currently, no studies have examined whether varying cholangiocarcinoma (CCA) prevalence levels are linked to previous OV infection nor have they provided comprehensive assessment and characterization of OV-associated CCA. OBJECTIVE: Our study examined the prevalence of serum IgG antibodies for OV-positive CCA cases and determined whether there were correlations of IgG antibodies with histopathologic features, HER2, PD-L1, and FGFR2 expression, as well as their roles on the patients’ survival. METHODS: The study involved 221 CCA surgical patients at Khon Kaen University Hospital, Thailand, from 2005 to 2017. Serum specimens were tested for OV IgG by ELISA. CCA tissue microarrays were used to examined for HER2, PD-L1, and FGFR2 expression. Logistic regression was used to investigate an association between factors and IgG. Cox regression was used to determine factors that affected CCA patient survival. RESULTS: IgG for OV were positive in 162 cases, and the prevalence was 73.3% (95% CI=68.0–78.7). About three quarters (78.3%) had large duct type tumors and concomitant intraductal papillary neoplasm of bile ducts (IPNB) occurred in 92 (50%) cases. HER2 expression was positive in 94 (61.4%) cases. Positive PD-L1 and FGFR2 expression occurred in 125 (83.9%) and 100 (67.1%) cases. IgG for OV had no significant correlation to any histological feature but had significant correlation with HER2 overexpression with adjusted OR=2.32 (95% CI=1.09–4.96, P=0.03). Cases of CCA with OV IgG positive had a significantly poor prognosis with adjusted HR=1.66 (95% CI=1.13–2.43, P=0.01). CONCLUSION: We found a high prevalence of serum IgG for OV-positive CCA patients and a correlation with overexpression of HER2. Moreover, IgG for OV and HER2 expression indicated poor survival of CCA. Therefore, future clinical studies for anti-HER2 treatments should focus on OV-associated CCA. Dove 2020-11-26 /pmc/articles/PMC7708780/ /pubmed/33273846 http://dx.doi.org/10.2147/IJGM.S282519 Text en © 2020 Titapun et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Titapun, Attapol
Techasen, Anchalee
Sa-Ngiamwibool, Prakasit
Sithithaworn, Paiboon
Luvira, Vor
Srisuk, Tharatip
Jareanrat, Apiwat
Dokduang, Hasaya
Loilome, Watcharin
Thinkhamrop, Bandit
Khuntikeo, Narong
Serum IgG as a Marker for Opisthorchis viverrini-Associated Cholangiocarcinoma Correlated with HER2 Overexpression
title Serum IgG as a Marker for Opisthorchis viverrini-Associated Cholangiocarcinoma Correlated with HER2 Overexpression
title_full Serum IgG as a Marker for Opisthorchis viverrini-Associated Cholangiocarcinoma Correlated with HER2 Overexpression
title_fullStr Serum IgG as a Marker for Opisthorchis viverrini-Associated Cholangiocarcinoma Correlated with HER2 Overexpression
title_full_unstemmed Serum IgG as a Marker for Opisthorchis viverrini-Associated Cholangiocarcinoma Correlated with HER2 Overexpression
title_short Serum IgG as a Marker for Opisthorchis viverrini-Associated Cholangiocarcinoma Correlated with HER2 Overexpression
title_sort serum igg as a marker for opisthorchis viverrini-associated cholangiocarcinoma correlated with her2 overexpression
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708780/
https://www.ncbi.nlm.nih.gov/pubmed/33273846
http://dx.doi.org/10.2147/IJGM.S282519
work_keys_str_mv AT titapunattapol serumiggasamarkerforopisthorchisviverriniassociatedcholangiocarcinomacorrelatedwithher2overexpression
AT techasenanchalee serumiggasamarkerforopisthorchisviverriniassociatedcholangiocarcinomacorrelatedwithher2overexpression
AT sangiamwiboolprakasit serumiggasamarkerforopisthorchisviverriniassociatedcholangiocarcinomacorrelatedwithher2overexpression
AT sithithawornpaiboon serumiggasamarkerforopisthorchisviverriniassociatedcholangiocarcinomacorrelatedwithher2overexpression
AT luviravor serumiggasamarkerforopisthorchisviverriniassociatedcholangiocarcinomacorrelatedwithher2overexpression
AT srisuktharatip serumiggasamarkerforopisthorchisviverriniassociatedcholangiocarcinomacorrelatedwithher2overexpression
AT jareanratapiwat serumiggasamarkerforopisthorchisviverriniassociatedcholangiocarcinomacorrelatedwithher2overexpression
AT dokduanghasaya serumiggasamarkerforopisthorchisviverriniassociatedcholangiocarcinomacorrelatedwithher2overexpression
AT loilomewatcharin serumiggasamarkerforopisthorchisviverriniassociatedcholangiocarcinomacorrelatedwithher2overexpression
AT thinkhamropbandit serumiggasamarkerforopisthorchisviverriniassociatedcholangiocarcinomacorrelatedwithher2overexpression
AT khuntikeonarong serumiggasamarkerforopisthorchisviverriniassociatedcholangiocarcinomacorrelatedwithher2overexpression